Wed, Feb 11, 2026
[Archive]
Volume 17, Issue 4 (December-2025 2025)
Iranian Journal of Blood and Cancer 2025, 17(4): 35-68 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sharma H, Mahto R R, Jha S K, Chauhan S, Khandelwal P, Tiwari S K. Rasayana-Based Adjuvant Strategies in Cancer Care: An Ayurvedic–Oncologic Perspective. Iranian Journal of Blood and Cancer 2025; 17 (4) :35-68
URL: http://ijbc.ir/article-1-1828-en.html
URL: http://ijbc.ir/article-1-1828-en.html
Himani Sharma1 
, Raja Ram Mahto2 , Sudhanshu Kumar Jha3 , Sonam Chauhan2 , Prachi Khandelwal2 , Sanjay Kumar Tiwari *4
, Raja Ram Mahto2 , Sudhanshu Kumar Jha3 , Sonam Chauhan2 , Prachi Khandelwal2 , Sanjay Kumar Tiwari *4
1- Department of Shalakya Tantra, Sanjeevani Ayurvedic Medical College, Gajraula, Uttar Pradesh, India.
2- Department of Kayachikitsa, All India Institute of Ayurveda, New Delhi, India.
3- Centre for Integrative Oncology, All India Institute of Ayurveda, New Delhi, India.
4- Department of Kayachikitsa, All India Institute of Ayurveda, New Delhi, India. ,Sktiwari17394@gmail.com
2- Department of Kayachikitsa, All India Institute of Ayurveda, New Delhi, India.
3- Centre for Integrative Oncology, All India Institute of Ayurveda, New Delhi, India.
4- Department of Kayachikitsa, All India Institute of Ayurveda, New Delhi, India. ,
Abstract: (13 Views)
Background: Cancer is a serious global health issue, and as multimodal therapies have advanced, treatment-related toxicities have a significant influence on function, compliance, and quality of life. Integrative oncology looks for supportive treatment and resilience-promoting supplementary techniques that are supported by research. Rasayana is the rejuvenating branch of Ayurveda that emphasizes on ojas (vitality), immunological balance, and metabolic homeostasis. It is probably useful for cancer care.
Objective: To integrate the safety considerations, emerging clinical cues, conceptual rationale, and implementation pathways of Rasayana-concordant botanicals and regimens as cancer care-modifying adjuncts.
Methods: Using iterative PubMed, Cochrane, EMBASE, AYUSH Portal, ctri.nic.in, ClinicalTrials.gov and WHO ICTRP searches until August 2025, a review was conducted in accordance with SANRA principles. Human clinical and translational data on Rasayana-compatible therapies given in addition to conventional oncologic treatments were, with focus on symptom clusters, safety, mechanistic plausibility, and herb–drug interactions. Classical Ayurvedic terms (e.g., Medhya, Balya, Ojovardhaka, and Raktaprasadana) were linked to their biological correlates and patient-reported outcomes using thematic data synthesis.
Results: Major Rasayana herbs with immunomodulatory, antioxidant, neuroendocrine, and mucosal-protective properties include Withania somnifera, Curcuma longa, Phyllanthus emblica, Tinospora cordifolia, and Ocimum tenuiflorum. Preliminary clinical data indicate improvements in symptoms. Safety themes highlight the importance of product authentication, pharmacovigilance, and monitoring potential herb-drug interactions, particularly those involving CYP3A4 and P-gp regulation.
Conclusion: In integrative oncology, Rasayana-based therapies show early supportive care and physiologically believable potential. Under multidisciplinary supervision, their usage should continue to be customized, safety-monitored, quality-assured, and adjunctive. Well-planned, oncology-focused clinical trials are required.
Objective: To integrate the safety considerations, emerging clinical cues, conceptual rationale, and implementation pathways of Rasayana-concordant botanicals and regimens as cancer care-modifying adjuncts.
Methods: Using iterative PubMed, Cochrane, EMBASE, AYUSH Portal, ctri.nic.in, ClinicalTrials.gov and WHO ICTRP searches until August 2025, a review was conducted in accordance with SANRA principles. Human clinical and translational data on Rasayana-compatible therapies given in addition to conventional oncologic treatments were, with focus on symptom clusters, safety, mechanistic plausibility, and herb–drug interactions. Classical Ayurvedic terms (e.g., Medhya, Balya, Ojovardhaka, and Raktaprasadana) were linked to their biological correlates and patient-reported outcomes using thematic data synthesis.
Results: Major Rasayana herbs with immunomodulatory, antioxidant, neuroendocrine, and mucosal-protective properties include Withania somnifera, Curcuma longa, Phyllanthus emblica, Tinospora cordifolia, and Ocimum tenuiflorum. Preliminary clinical data indicate improvements in symptoms. Safety themes highlight the importance of product authentication, pharmacovigilance, and monitoring potential herb-drug interactions, particularly those involving CYP3A4 and P-gp regulation.
Conclusion: In integrative oncology, Rasayana-based therapies show early supportive care and physiologically believable potential. Under multidisciplinary supervision, their usage should continue to be customized, safety-monitored, quality-assured, and adjunctive. Well-planned, oncology-focused clinical trials are required.
Keywords: Rasayana, Ayurveda, Integrative Oncology, Immunomodulation, Redox signaling, Chemotherapy toxicity
: Review Article |
Subject:
Adults Hematology & Oncology
Received: 2025/11/4 | Accepted: 2025/12/21 | Published: 2025/12/30
Received: 2025/11/4 | Accepted: 2025/12/21 | Published: 2025/12/30
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
- Iranian Journal of Blood and Cancer
- Journal Tel: +989369936116
- Publisher Tel: +982122275917
- Mail: Info@ijbc.ir
